Bevacizumab in adult malignant brainstem gliomas.
Raza
Shahzad
S
Department of Neuro-Oncology, New York University Langone Medical Center, New York, NY, 10016, USA. shahzad.raza@nyumc.org.|Department of Radiation Oncology, New York University Langone Medical Center, New York, NY, 10016, USA. shahzad.raza@nyumc.org.
Donach
Martin
M
Department of Radiation Oncology, New York University Langone Medical Center, New York, NY, 10016, USA.
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020295:Brain Stem Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab